-

07:40:14 AM

KNTE Stock News

KNTE - Kinnate Biopharma Inc

03/15/23 4:05 PM

Nasdaq : KNTE

earnings

Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate Updates

Announced Phase 1 monotherapy dose escalation data for investigational pan-RAF inhibitor exarafenib (KIN-2787) was selected for an oral presentation at the American Association for Cancer Research 2023 Annual Meeting Announced the company has initiated enrollment of patients into the monotherapy

RHEA-AI

very positive

03/14/23 6:09 PM

Nasdaq : KNTE

conferencesclinical trial

Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual Meeting

Company has initiated enrollment of patients into the monotherapy expansion cohorts Company to host a virtual investor webcast on April 17, 2023, to discuss the AACR results and dose expansion strategy, and to provide additional pipeline updates SAN FRANCISCO and SAN DIEGO, March 14, 2023 (GLOBE

RHEA-AI

neutral

02/21/23 4:05 PM

Nasdaq : KNTE

acquisitionclinical trial

Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China Joint Venture, Kinnjiu Biopharma Inc., and Initiation of Phase 1 Clinical Trial for Exarafenib (KIN-2787) in People's Republic of China

Kinnate to retain Kinnjiu’s cash, intellectual property and other assets, including key personnel and legal entity structure Kinnate’s cash runway still expected to fund current operations into mid-2024 Trial sites open in People's Republic of China (PRC) and Taiwan for ongoing Phase 1 clinical

RHEA-AI

neutral

02/14/23 4:05 PM

Nasdaq : KNTE

Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Kinnate’s investigational pan-FGFR

RHEA-AI

very positive

02/06/23 4:05 PM

Nasdaq : KNTE

conferences

Kinnate Biopharma Inc. to Participate in the 2023 SVB Securities Global Biopharma Conference

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief executive officer, Nima Farzan, will participate in a fireside chat at the SVB Securities Global Biopharma

RHEA-AI

neutral

01/26/23 4:05 PM

Nasdaq : KNTE

management

Kinnate Biopharma Inc. Adds Global Business and Oncology Expertise to Board of Directors with Appointment of Jill DeSimone as Independent Director

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its board of directors has appointed a new independent director, Jill DeSimone, who will join effective March 1,

RHEA-AI

very positive

01/17/23 4:05 PM

Nasdaq : KNTE

conferences

Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced the poster presentation of the design and rationale of a Phase 1 trial-in-progress (KN-4802, NCT05242822) evaluating the

RHEA-AI

neutral

11/10/22 4:05 PM

Nasdaq : KNTE

earnings

Kinnate Biopharma Inc. Announces Third Quarter 2022 Financial Results and Recent Corporate Updates

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company,

RHEA-AI

neutral

10/11/22 4:05 PM

Nasdaq : KNTE

clinical trial

Kinnate Biopharma Inc. Announces Recent Corporate Updates, Including on the Ongoing KIN-2787 Monotherapy Dose Escalation from Global Phase 1 Trial

KIN-2787 cleared the predicted efficacious dose at 300 mg bid; dose escalation continues with maximum tolerated dose not yet determined KIN-2787 achieved meaningful exposures that were dose proportional and exceeded the predicted efficacious thresholds based on preclinical models Observed

RHEA-AI

neutral

09/21/22 4:05 PM

Nasdaq : KNTE

Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-2787, an Investigational Pan-RAF Inhibitor

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Kinnate’s investigational pan-RAF

RHEA-AI

very positive

1 2 3 4 5 6 Next

KNTE Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.kinnate.com
Security nameKinnate Biopharma Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees61

About Kinnate Biopharma Inc

Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate’s mission is to expand the reach of targeted therapeutics by developing products for underserved populations. Kinnate utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which it refers to as the Kinnate Discovery Engine, to develop targeted therapies. Based in San Francisco and San Diego, California, the Kinnate team is composed of drug discovery experts supported by a distinguished group of scientific advisors.